

Supplementary Table 5. Risk factors for death in BCLC C stage patients with HCC (n=538)

Variable	Univariate			Multivariate		
	HR	95% CI	P-value	HR	95% CI	P-value
Etiology						
HBV	Ref					
HCV	0.873	0.576-1.324	0.522			
NBNC	0.897	0.676-1.189	0.445			
Age (years)	1.003	0.994-1.013	0.491			
Male sex	0.916	0.712-1.179	0.497			
Hypertension	0.932	0.749-1.160	0.531			
Diabetes	0.957	0.754-1.214	0.715			
Smoking	0.976	0.795-1.198	0.815			
Alcohol	0.905	0.733-1.118	0.354			
Albumin (g/dL)	0.573	0.479-0.686	<0.001	0.890	0.561-0.849	<0.001
Total bilirubin (mg/dL)	1.061	1.022-1.101	0.002	1.011	0.967-1.058	0.618
Prothrombin time (INR)	5.142	3.117-8.483	<0.001	2.675	1.458-4.907	0.001
AST (U/L)	1.003	1.002-1.004	<0.001	1.001	1.000-1.002	0.138
ALT (U/L)	1.000	1.000-1.001	0.422			
Tumor size (cm)	1.021	0.996-1.047	0.107			
Macrovascular invasion	1.023	0.784-1.335	0.867			
Extrahepatic metastasis	1.831	1.438-2.332	<0.001	1.715	1,336-2.201	<0.001
AFP (ng/mL)	1.000	1.000-1.000	<0.001	1.000	1.000-1.000	<0.001
PIVKA-II (mAU/mL)	1.000	1.000-1.000	<0.001	1.000	1.000-1.000	<0.001

BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non-B non-C; INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by the absence of vitamin K or antagonist-II; 95% CI, 95% confidence interval; HR, hazard ratio; Ref, reference.